Hang Seng Pharmaceutical ETF (159892) bottom pull up nearly 18%! Its holdings include JD Health and Alibaba Health Information Technology in Internet medicine, as well as innovative and R & D enterprises such as Zai Lab Limited, Kangfang Bio, Rongchang Bio, Wuxi Biologics, Wuxi Apptec and so on. Hang Seng Pharmaceutical ETF (159892) obtained funds for 7 days in a row, and the turnover rate ranked first in similar products, with obvious volume at the bottom of the stage! After the previous over-falling Hong Kong stock medicine has experienced continuous adjustment, the further downward space is limited, and from the valuation and other indicators, it has a higher margin of safety and higher investment value.
Huaxia Fund believes that in terms of industrial policy, the policy direction of "building a number of new growth engines such as biotechnology and high-end equipment" is expected to support the long-term development of the industry. From the perspective of health insurance policy, the performance of Hang Seng Pharmaceutical in the fourth quarter is worthy of attention, such as frequent favorable policies, warmer market sentiment, layout of biotechnology, innovative drugs, CXO and other areas related to independent control.